Targeting TROP2 in treatment‑resistant non‑small cell lung cancer harboring the KRAS G12C mutation and TROP2 upregulation: A case report
The patient experienced a 42% reduction in tumor size from the baseline (February 2023), as measured based on RECIST 1.1.
Non-small cell lung cancer (NSCLC) with KRAS G12C mutation and TROP‑2 upregulation is largely refractory to standard therapies. This case report describes a 65‑year‑old male with metastatic lung adenocarcinoma (NSCLC) who achieved a 42% reduction in target lesions over 34 months of treatment with the TROP‑2‑targeting antibody‑drug conjugate (ADC) SKB264, with no serious adverse events. The durable response suggests that TROP‑2‑directed ADC therapy may represent a novel therapeutic option for NSCLC patients harboring KRAS G12C mutations and TROP‑2 upregulation.
KRAS G12C mutations are common in NSCLC and are associated with poor prognosis and limited treatment options. TROP‑2 is a surface antigen that can be targeted by ADCs, offering a potentially effective therapeutic strategy for this subset of patients.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT